Quick Buzz Feed
The eighth cohort of the Biomedical Innovation Challenge showcased its innovations and development plans during a lightning round of pitches and judges’ questions on June 4 in the Belfer Research Building.
The annual BioVenture eLab's Biomedical Innovation Challenge culminated on June 4, featuring the eighth cohort of Weill Cornell faculty and trainees. This event provides a platform for innovators to present their early-stage projects and development plans, aiming to translate scientific discoveries into commercial products. The program transforms researchers into entrepreneurs, fostering solutions beyond current standards of care. This year, five teams participated, with three focusing on cell therapies and two introducing AI-related technologies for the first time.
Five distinct teams presented their groundbreaking innovations during the lightning-round pitches: * **AdherePath:** Led by Dr. Samprit Banerjee, this project utilizes artificial intelligence to enhance treatment adherence among patients suffering from depression. * **ASTRA:** Conceived by Dr. Judy Zhong, ASTRA introduces an AI-driven system designed to automate and streamline the entire workflow of clinical trials. * **Nodera Biotherapeutics:** Based on the research of Dr. Jonathan Villena-Vargas, this innovative approach involves engineering T cells derived from lymph nodes to develop a novel therapy against solid tumors. * **Storgan Therapeutics:** Represented by Drs. Anna Ada Dattoli and Shahin Rafii, this team is developing a cell therapy for Type 1 diabetes by transforming gastric stem cells. * **Styr Therapeutics:** Under the leadership of Drs. Carlo Bosi and Giovanni Medico, Styr Therapeutics aims to advance a highly targeted CAR-T cell therapy specifically for solid tumors.
The competing scientist-entrepreneurs were evaluated by a distinguished panel of three experts. These judges, possessing extensive backgrounds in biomedical technology, engineering, investment, and launching life science startups, included Dr. Brandy Houser (co-founder and CEO of Traverse Biotech), Dr. Matias Porras Paniagua (vice president at Insight Partners), and Dr. Carlo Yuvienco (director of Ford Center Incubator at The Rockefeller University). They rigorously questioned the founders on their business models, exit strategies, FDA approval pathways, and the scientific intricacies behind their findings.
Styr Therapeutics, led by Drs. Carlo Bosi and Giovanni Medico, was awarded first place and a $20,000 prize for their work addressing the efficacy challenges in solid-tumor CAR-T treatment. Their team identified 4-1BBL as a crucial biomarker and potential target in multiple solid tumors through a unique discovery engine. This led to the development of a CAR-T candidate that has demonstrated superior performance compared to existing lymphoma therapies in initial mouse studies. Styr Therapeutics plans to conduct safety and toxicology studies, aiming to raise $5 million initially, with an additional $7 million for subsequent development phases, leveraging their platform to build a pipeline of multiple assets.
Two teams tied for second place, each receiving a $10,000 prize. Nodera Biotherapeutics, championed by Dr. Jonathan Villena-Vargas, showcased its capability to manufacture stem cells from lymph nodes within a few weeks, offering a promising approach for solid tumors. They are currently seeking funding with expectations to commence Phase 1 testing at Weill Cornell within the next 18 months. ASTRA, presented by Dr. Judy Zhong, impressed with its AI agents designed to automate the clinical trial process across various fragmented tools, from IRB submissions to participant screening and data management. Having completed Phase 1 (core architecture and UI), ASTRA requires $5 million to advance to Phase 2 for enrollment testing and later Phase 3 for large-scale pharmaceutical trials.
Loren Busby, director of BioVenture eLab, emphasized that the true value of the challenge extends beyond monetary awards, highlighting that success is fostered through persistence, continuous learning, collaboration, and a willingness to move forward. Dr. Lisa Placanica, senior managing director of the Center for Technology Licensing at Weill Cornell Medicine, underscored the critical role of commercializing academic innovations in advancing healthcare and catalyzing further discoveries. The BioVenture eLab program, through its weekly sessions, industry mentorship, and pitch crafting, cultivates the entrepreneurial mindset and skills necessary for researchers and clinicians to engage with industry collaborators and potential investors.